Nanjing Jiqun Pharmaceutical Co., Ltd.’s Jianuosi® (doxylamine succinate tablets), developed over 12 years, has recently been approved by the National Medical Products Administration (NMPA), making it the only new therapeutic drug specifically targeting "short-term insomnia." It is coming Soon and is expected to fill a blue-ocean market gap for short-term insomnia.
According to the International Classification of Sleep Disorders (ICSD-3) guidelines, insomnia is classified into "short-term insomnia" and "chronic insomnia." The vast majority of currently marketed insomnia medications are targeted at chronic insomnia. These drugs often have shortcomings such as addiction, dependence, tolerance, and withdrawal symptoms (cannot be discontinued abruptly). Consequently, they are classified as "psychotropic substances," subject to strict control, limited to specialized departments like psychiatry in hospitals, requiring prescriptions from specialists, and with strict limits on prescription volume. As a medication intended for long-term benefit, their "accessibility" is very difficult.